Trials / Completed
CompletedNCT02223078
Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.
Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Two Centre Study to Determine the Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Cancer Advances Inc. · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Pancreatic, gastric, and colorectal cancers have all been shown to overexpress the gastrin gene and to be sensitive to the trophic effects of the gastrin in animal models. The hypothesis of this study is that G17DT will elicit specific and high-affinity antibodies that will bind gastrin-17, thus preventing the trophic activity of cancer cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | G17DT | |
| BIOLOGICAL | Placebo Comparator |
Timeline
- Start date
- 2000-07-01
- Primary completion
- 2001-08-01
- Completion
- 2001-11-01
- First posted
- 2014-08-22
- Last updated
- 2017-06-20
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02223078. Inclusion in this directory is not an endorsement.